[ap17]

What's going on here, besides the share price approaching CV's.

[Wolf-man jack]

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=174604606

https://finance.yahoo.com/news/organigram-reports-third-quarter-fiscal-103000048.html

[ap17]

ouch!!

[Thomas@yahoo]

More GREAT NEWS FOR CV SCIENCES
https://www.greenmarketreport.com/california-cannabis-business-orgs-raise-red-flags-over-proposed-hemp-supply-chain-integration/

[Wolf-man jack]

“ Charlotte's Web Holdings, Inc. (TSE:CWEB) just released its latest quarterly report and things are not looking great. It definitely looks like a negative result overall with revenues falling 14% short of analyst estimates at US$12m. Statutory losses were US$0.07 per share, 40% bigger than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. Readers will be glad to know we've aggregated the latest statutory forecasts to see whether the analysts have changed their mind on Charlotte's Web Holdings after the latest results.

Following the recent earnings report, the consensus from three analysts covering Charlotte's Web Holdings is for revenues of US$50.8m in 2024. This implies a measurable 6.9% decline in revenue compared to the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 33% to US$0.19. Before this earnings announcement, the analysts had been modelling revenues of US$57.5m and losses of US$0.22 per share in 2024. We can see there's definitely been a change in sentiment in this update, with the analysts administering a meaningful downgrade to next year's revenue estimates, while at the same time reducing their loss estimates.

The consensus price target fell 14% to CA$0.65, with the dip in revenue estimates clearly souring sentiment, despite the forecast reduction in losses.”


https://finance.yahoo.com/news/earnings-release-heres-why-analysts-122818344.html

[MaxwellE]

$.15 per share, that's about $.10 per share more than it's worth...M

[GE_Jim]

Well thats interesting. we'll see how it plays

[DarthYoda]

"Citing failures to protect public health, lawmaker looks to remove FDA's food authority":
August 2nd 2024

Rep. Rosa DeLauro (D-CT), who's been in Congress for more than three decades, has had enough.
She's introduced legislation to remove the FDA's food authority and start fresh with a new agency: The Federal Food Administration.
https://wjla.com/resources/pdf/1425c052-a30c-4578-90ea-6744f83ac635-TAM24855.pdf

The agency sent us the below statement:
"As you may be aware, in May the FDA reached a significant milestone with approval of its reorganization involving the creation of a unified Human Foods Program (HFP), adoption of a new model for its field operations and other significant modernization efforts. The reorganization implementation is currently targeted for Oct. 1, 2024, notably enhancing the agency’s ability to oversee and protect the human food supply and other products the FDA regulates. The reorganization will enable the FDA to be more efficient, nimble and prepared for the ever-changing and complex industries we regulate, new food and medical product technologies, as well as the impacts of globalization, climate change and other factors that require the agency to quickly adapt.

Additional information can be found here:
https://www.fda.gov/about-fda/fda-organization/fda-modernization-efforts-establishing-unified-human-foods-program-new-model-field-operations-and

https://wjla.com/news/spotlight-on-america/toxic-baby-food-fda-citing-failures-protect-public-health-formula-bacteria-heavy-metals-tainted-applesauce-rosa-delauro-connecticut-test-contaminants-safe-products

[DarthYoda]

You got it. Here's something from the Gov side...
"Congress Advances Cannabis and Hemp Proposals":
July 29, 2024
https://www.jdsupra.com/legalnews/congress-advances-cannabis-and-hemp-5541083/

[GE_Jim]

Thanks for the post. I have taken a step back, need to see clarity from the gov. side. Just going to enjoy summer till then.

[Wolf-man jack]

https://finance.yahoo.com/news/charlottes-2024-second-quarter-earnings-123700472.html

[DarthYoda]

I found a recently published research paper that was funded by Charlotte's Web, and I threw in a couple more papers below it as well. The one funded by Charlotte's Web is focused on a new cannabinoid called Cannabielsoin or CBE, (there is S-CBE and R-CBE, this paper focused on S-CBE), which is an oxidation product of CBD. You guys know I love seeing stuff like this...Enjoy!

"Cannabielsoin (CBE), a CBD Oxidation Product, Is a Biased CB1 Agonist":
Published: 12 July 2024

Funding
Funding for this study was provided by Charlotte’s Web.

https://www.mdpi.com/2227-9059/12/7/1551

"Cannabidiol ameliorates lipopolysaccharide-induced cardiovascular toxicity by its antioxidant and anti-inflammatory activity via regulating IL-6, Hif1a, STAT3, eNOS pathway":
18 July 2024

Results
Histopathological analysis of the LPS group showed moderate hyperemia, hemorrhages, edema, inflammation, and myocardial cell damage. There was a slight to moderate increase in Cox-1, G-CSF, and IL-3 immunoexpressions, along with enhanced expressions of IL-6, Hif1a, and STAT3 genes, and decreased expressions of eNOS genes. Additionally, there were increased levels of TOS and decreased TAS levels observed biochemically. CBD treatment effectively reversed and improved all of these observed changes.

Conclusions
CBD protects the heart and aorta against systemic inflammation through its antioxidant and anti-inflammatory activity via regulating IL-6, Hif1a, STAT3, and eNOS intracellular pathways.

https://link.springer.com/article/10.1007/s11033-024-09772-3

"Cannabinoid Content and Label Accuracy of Various Hemp-Derived Haircare, Cosmetic, and Edible Products Available at Retail Stores and Online in the United States":
19 July 2024

Results: Ninety-seven products were purchased (35 in-store, 62 online). Of the 71 products with a specific total CBD amount on the label, 35 (49%) were underlabeled (>10% more CBD than advertised), 27 (38%) were overlabeled (>10% less CBD than advertised), and 9 (12.7%) were accurately labeled (within ±10% of labeled CBD). The median (range) percentage deviations were -53% (-100%–76%) for haircare products, +18% (-100%-1076%) for cosmetics, and -1% (-100%-4468%) for food/drinks. CBD label accuracy did not differ significantly between products with external testing claims versus those without (t40 = 0.23, p = 0.82). Overall, 24% of the 97 (total) products made a cosmetic or beauty claim (e.g., “skin looks more youthful”), 40% made a therapeutic claim (e.g., “pain relief”), and 86% made a health halo effect claim (e.g., “paraben-free,” “dye-free,” etc.). Most products (63%) did not include a disclaimer that claims had not been evaluated by the FDA.
Conclusions: Most of the products included in this sample were inaccurately labeled for CBD content, including those claiming to have been tested by third party laboratories. A notable finding was that 10 products did not contain any CBD. Many products made therapeutic claims or used marketing tactics to seemingly convey they were safe/healthy, but only about one-third included disclaimers that these statements had not been evaluated by the FDA. These findings highlight the need for proper regulatory oversight of cannabinoid-containing products to ensure quality assurance and deter misleading or unfounded health claims in product marketing.

https://www.liebertpub.com/doi/abs/10.1089/can.2024.0039

[DarthYoda]

"Case Report: Cannabis Oil Treats Common Skin Disease in Dog":
JUL 11, 2024

Veterinary students and scientists in Brazil used cannabis oil to successfully treat a dog with a common skin disease that did not respond to previous treatment. The corresponding study was published in Frontiers in Veterinary Science.

Discoid lupus erythematosus (DLE) is a common autoimmune disease that typically affects the skin on the nose and ears of dogs. It is characterized by inflammation, loss of hair pigment, and redness, which can lead to crusting and ulceration. The condition's underlying cause remains unknown; however, it is thought to arise from a mix of genetics, infections, hormones, and sun exposure. Current treatments include corticosteroids to reduce inflammation; however, these carry a risk of unwanted side effects.

Previous research suggests that cannabinoids cannabidiol (CBD) and tetrahydrocnnabidiol (THC) reduce inflammation in both dogs and humans without any detrimental side effects.

In the current case report, a two-year-old female mixed-breed dog with DLE was not responding to corticosteroids and other medications. The researchers thus decided to treat the dog with cannabis oil.

After some experimentation, they found that cannabis oil containing CBD and THC on a ratio of 3:1 worked best. To begin, the dog was given a single drop orally once daily for three days to test for negative reactions. The treatment continued after no negative reactions were reported, and the dosage was slowly adjusted until the minimum effective dose was found. After several weeks, some signs of DLE started to disappear, and after a year, all symptoms were relieved.

"After 1year, the dog remains clinically stable on a low dose of full-spectrum CBD-rich oil. No evidence of DLE recurrence was observed," wrote the researchers in their paper.

“This case suggests that cannabinoid therapy (CT) may be a viable alternative or complementary therapy for DLE in dogs, particularly for those experiencing adverse effects from conventional treatments. Further research is warranted to confirm the efficacy and safety of CT for DLE management in dogs,” continued the researchers.

https://www.labroots.com/trending/cannabis-sciences/27420/report-cannabis-oil-treats-common-skin-disease-dog-2
Here is the actual paper...
"Case report: Cannabinoid therapy for discoid lupus erythematosus in a dog":
https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2024.1309167/full

[ap17]

NICE!! the agencies are a cancer to the world.

[DarthYoda]

Here's an article that gets into more specifics...
"How the Supreme Court Overturning a Case Against Chevron Oil Threw the Marijuana Industry into Chaos":
Jul 8, 2024

For instance, if a federal agency says a product can't contain a certain amount of CBD, companies can more easily challenge that decision in court. The agency can no longer rely solely on its supposed expertise to defend its rules.

https://cannabis.net/blog/news/how-the-supreme-court-overturning-a-case-against-chevron-oil-threw-the-marijuana-industry-into

[DarthYoda]

Yeah, there's always that question of when. Maybe the Chevron ruling will combine with rescheduling to make schedule 3 even more meaningful to companies. At the very least, companies soon won't have to remove every molecule of THC to gain FDA approval...
"Cannabis Medications Could Be Eligible For FDA Approval Under Proposed DEA Rules":
July 8, 2024

The US Drug Enforcement Administration has proposed new rules that mean, for the first time, medications containing delta-9 THC from the cannabis plant could be eligible for approval by the US Food and Drug Administration (FDA).

https://www.cannabisculture.com/content/2024/07/08/cannabis-medications-could-be-eligible-for-fda-approval-under-proposed-dea-rules/

[Thomas@yahoo]

https://www.barchart.com/stocks/quotes/CWBHF/opinion

[GE_Jim]

Thats a good info post. The question will be on how long.

[DarthYoda]

"Supreme Court’s Chevron Doctrine Ruling Could Limit FDA’s Regulatory Authority":
Jul 01, 2024

In overruling Chevron on Friday, the Supreme Court ushered in a new framework, dubbed Loper Bright. Courts are now required to “exercise their independent judgement in deciding whether an agency has acted within its statutory authority” and “may not defer to an agency interpretation of the law simply because a statute is ambiguous.”

This new framework could have significant consequences for the FDA and its regulatory authority, according to an analysis by global law firm Sidley.

The firm contends that Loper Bright could potentially open the regulator’s drug approvals to legal challenges. Companies need to provide “substantial evidence” that their drug candidates are safe and effective before securing approval, but courts in the past have found this ambiguous and have allowed the FDA to ask for additional requirements, such as data showing that the candidate’s effects are clinically meaningful, according to Sidley.

Under Loper Bright, more companies could try and challenge this approach, Sidley warned.

The overturning of Chevron could also pose some jurisdictional questions for the FDA, which is typically given the leeway to decide what constitutes a dietary supplement or a device product. These kinds of determinations affect how products are regulated, produced, or imported—and companies can now mount stronger challenges to this function by the FDA.

https://www.biospace.com/article/supreme-court-s-chevron-doctrine-ruling-could-limit-fda-s-regulatory-authority/
Here are two opposing opinions on how the chevron decision could affect rescheduling...
https://www.marijuanamoment.net/the-supreme-court-nuked-cannabis-rescheduling-with-its-chevron-ruling-op-ed/
https://www.marijuanamoment.net/reports-of-marijuana-reschedulings-chevron-related-death-are-greatly-exaggerated-op-ed/

[DarthYoda]

FYI-"The FDA’s power to determine a drug’s exclusivity or review tobacco marketing applications faces fresh vulnerability to legal battles after the Supreme Court’s decision to nix a legal doctrine that empowered agency interpretations.

The US Supreme Court’s June 28 opinion in Loper Bright Enters. v. Raimondo is expected to open the floodgates for litigation against the Food and Drug Administration after ending the decades-old Chevron doctrine. Under the 1984 decision in Chevron v. Natural Resources Defense Council, courts had accepted a federal agency’s reasonable interpretation of its rulemaking authority when its statute was determined ambiguous."
https://news.bloomberglaw.com/health-law-and-business/fda-drug-approvals-rulemaking-are-tested-after-chevron-decision

[Thomas@yahoo]

https://hemptoday.net/struggles-continued-for-charlottes-web-in-first-quarter-as-losing-streak-continued/

[Thomas@yahoo]

🎉 Big News! 🎉
We’re thrilled to congratulate long-time U.S. Hemp Roundtable member, @medterracbd, on an incredible achievement! Their high-quality CBD topicals are now available on retail shelves and online at Walmart! pic.twitter.com/1CTIVrSOjo

— US Hemp Roundtable (@HempRoundtable) June 26, 2024

[Wolf-man jack]

This will open the door for +Plus CBD

https://finance.yahoo.com/news/charlottes-debuts-walmart-cbd-topical-121500999.html

[ap17]

.10 ea coming, wait a bit longer to get 3 for a quarter.

[N.C.LUCKY(7)]

It will hit 0.10 in July.. Great buying opportunity an the closer we get to November elections the cannabis sector will start heating up...

[Wolf-man jack]

Another Cash Burn 🔥 In The Anus YQU Understand. Who takes his place, Smokey Joe? Have Mercy WQLF Ahooooooo

http://archive.fast-edgar.com/20240614/AWZZV62CZ22BRZZ222242ZZZQU79ZZTS4262/

Wolfman Jack Says: CWBHF Shareholders get humped over again YQU Understand. Have Mercy Ahooooooo

[Wolf-man jack]

In my opinion, It doesn’t appear that BAT is investing in OGI and CWBHF for any other reason, but to make sure their investments are protected. Most likely there would be no mergers planned for the two entities along with BAT. Poison pills 💊 in both agreements. But agreements can be negotiated for any and all reasons as long as both parties agree. The recent tranche of funds for the Jupiter program of acquiring other cannabis companies could prove me wrong. With the limited amount of funds available, they are considering smaller companies. Unless, they offer equity and stock for any possible acquisition of CWBHF by OGI.

“ BAT will subscribe for 12,893,175 million shares on the closing of the first tranche (currently expected to be on or around January 16, 2024) for gross proceeds of C$41.5 million with the remaining 25,786,350 shares to be subscribed for in two further equal tranches on or around August 30, 2024 and February 28, 2025.

To the extent BAT exceeds 30.0% holding of outstanding Common Shares, it will be issued non-voting Class A convertible preferred shares ("Preferred Shares"). Accordingly, in aggregate, based on Organigram’s current 81,161,630 Common Shares outstanding, 12,999,231 Common Shares will be issued, and the remaining 25,680,294 shares will be initially issued as Preferred Shares. The Preferred Shares will be eligible for conversion into voting Common Shares at BAT’s option, provided that such conversion would not result in BAT’s voting interest in the Company exceeding 30%.

In connection with the closing of the first tranche of the Investment and subject to approval by Organigram’s shareholders, the Company will file articles of amendment to create the new class of Preferred Shares to be issued to BAT in the Investment.

Class A Preferred Shares

Each Preferred Share shall be economically equivalent to a Common Share and will be convertible into Common Shares at the option of BAT without payment of any additional consideration. The conversion ratio shall initially be one-for-one, and post-issuance shall increase at a rate of 7.5% per annum, compounded annually, until such time as the Preferred Shares are converted into Common Shares or the aggregate equity interest of BAT in Organigram (inclusive of both the Common Shares and Preferred Shares as if converted into Common Shares) reaches 49%. BAT shall be periodically required to convert Preferred Shares to the extent that it holds less than 30% of the Common Shares outstanding”

[Wolf-man jack]

“Investor Rights Agreement, dated November 14, 2022, by and between Charlottes Web Holdings, Inc. and BT DE Investments, Inc. a wholly-owned subsidiary of BAT Group“

https://contracts.justia.com/companies/charlottes-web-holdings-inc-14559/contract/261689/

“ Since March 2021, Organigram’s partnership with BAT has gone from strength-to-strength, most significantly the progress achieved as part of the PDC agreement.”

https://finance.yahoo.com/news/organigram-announces-c-124-6-110000751.html

“BT DE INVESTMENTS INC. ACQUIRES STAKE IN CHARLOTTE'S WEB HOLDINGS, INC.
NEWS PROVIDED BY
BT DE Investments Inc.
Nov 15, 2022, 08:19 ET
WILMINGTON, Del., Nov. 15, 2022 /CNW/ - BT DE Investments Inc. (the "Purchaser") announced today that it has acquired (the "Transaction") C$75,341,080 aggregate principal amount of a 5.00% senior unsecured convertible debenture due 2029 (the "Convertible Debenture"), which is convertible, in whole or in part, at any time and from time to time, into 37,670,540 common shares (the "Common Shares") of Charlotte's Web Holdings, Inc. (the "Issuer") at a price of C$2.00 per Common Share (the "Conversion Price"). The Convertible Debenture provides for the adjustment of the Conversion Price in certain customary events. The Purchaser is a wholly owned indirect subsidiary of British American Tobacco p.l.c.

Immediately prior to the Transaction, the Purchaser did not have beneficial ownership of any securities of the Issuer. Immediately after the Transaction, and assuming the conversion of the Convertible Debenture in full, the Purchaser acquired beneficial ownership of 37,670,540 Common Shares, representing approximately 19.9% of the issued and outstanding Common Shares (calculated on a non-diluted basis).”

“ The Purchaser entered into the Transaction as part of an investment in the Issuer and intends to review its investment in the Issuer on a continuing basis. The Purchaser may, subject to the terms of the investor rights agreement entered into between the Purchaser and the Issuer dated November 14, 2022, depending upon a number of factors including market and other conditions, increase or decrease its beneficial ownership, control, direction or economic exposure over securities of the Issuer.”


https://www.newswire.ca/news-releases/bt-de-investments-inc-acquires-stake-in-charlotte-s-web-holdings-inc--851723097.html

This statement would allow BAT to bring OGI and CWBHF together as a merger opportunity. Depending on the BAT and OGI agreement, which I haven’t researched, then BAT may be able to bring both entities under the BAT Umbrella.

“ The Purchaser may not convert the Convertible Debenture, in whole or in part, if and to the extent that, as a result of such conversion, the Purchaser would beneficially own or exercise control or direction over in excess of 19.9% of the number of Common Shares outstanding immediately after giving effect to such conversion.”

[cashbyers]

Good points! Thanks for your thoughts

[Wolf-man jack]

WQLF SAYS; It there is a likelihood of a Merger, it would be OGI acquiring CWBHF. This would be more feasible if BAT converts CWBHF debt into CWBHF Equity / shares. This would allow more leverage for shareholder approval of any M&A between OGI and CWBHF. If CWBHF sales continue on their current downward trajectory, and the continuation of large increases in Cash burn, then the merger and acquisition will have to go into effect. The lower the price per share of CWBHF will benefit OGI and BAT. In my opinion, the current and future CWBHF shareholders will be the losers in the long run if this is what BAT has in mind. The bottom price per share of CWBHF in the near future could end up between 10 and 15 cents.

“ Most of the money will be used by Organigram to fund a strategic investment pool named Jupiter, which will target investments in emerging cannabis markets.”

https://mjbizdaily.com/tobacco-giants-124-million-investment-in-marijuana-firm-organigram-approved/

CWBHF

Balance Sheet
Total Cash (mrq) 38.51M
Total Cash Per Share (mrq) 0.25
Total Debt (mrq) 60.14M
Total Debt/Equity (mrq) 128.86%
Current Ratio (mrq) 3.48
Book Value Per Share (mrq) 0.30

[Wolf-man jack]

https://finance.yahoo.com/news/charlottes-announces-shareholder-meeting-voting-132800795.html

Cashburners Said; How LOW Can YQU Go?

Don’t overlook this underwater synergy!

Wolfman Jack Said; Jack Be Nimble Jack Be Quick YQU Understand. Have Mercy Ahooooooo